Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis

Background Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies. Aim To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. Methods We conduc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wannhoff, Andreas (VerfasserIn) , Brune, Maik (VerfasserIn) , Knierim, Johannes (VerfasserIn) , Weiss, Karl Heinz (VerfasserIn) , Rupp, Christian (VerfasserIn) , Gotthardt, Daniel (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 27 January 2019
In: Alimentary pharmacology & therapeutics
Year: 2019, Jahrgang: 49, Heft: 6, Pages: 769-778
ISSN:1365-2036
DOI:10.1111/apt.15146
Online-Zugang:Verlag, Volltext: https://doi.org/10.1111/apt.15146
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15146
Volltext
Verfasserangaben:Andreas Wannhoff, Maik Brune, Johannes Knierim, Karl Heinz Weiss, Christian Rupp, Daniel N. Gotthardt

MARC

LEADER 00000caa a2200000 c 4500
001 1662607059
003 DE-627
005 20230426172430.0
007 cr uuu---uuuuu
008 190401s2019 xx |||||o 00| ||eng c
024 7 |a 10.1111/apt.15146  |2 doi 
035 |a (DE-627)1662607059 
035 |a (DE-599)KXP1662607059 
035 |a (OCoLC)1341205768 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Wannhoff, Andreas  |d 1983-  |e VerfasserIn  |0 (DE-588)1045619833  |0 (DE-627)774667486  |0 (DE-576)39911095X  |4 aut 
245 1 0 |a Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis  |c Andreas Wannhoff, Maik Brune, Johannes Knierim, Karl Heinz Weiss, Christian Rupp, Daniel N. Gotthardt 
264 1 |c 27 January 2019 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.04.2019 
520 |a Background Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies. Aim To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. Methods We conducted a retrospective analysis of CA19-9 values in patients who had primary sclerosing cholangitis, with and without biliary malignancy. We calculated the index of individuality and reference change value in patients who were cancer-free. Long-term analysis of CA19-9 in cancer-free patients was performed and we assessed the change of CA19-9 prior to diagnosis of cancer. Results We obtained 1818 CA19-9 values from 247 patients, including 32 with malignancy. Median CA19-9 in cancer-free individuals was 15.6 U/mL. The index of individuality was 0.37 and the reference change value was 46.23%. In cancer-free patients, no significant change in CA19-9 was observed at 1, 2, 5, 7, 10, 15, and 20 years after initial diagnosis of primary sclerosing cholangitis. In patients with biliary tract cancer, CA19-9 was higher at 3 months prior to diagnosis (P < 0.05) than at 6 months before diagnosis and was also higher than at 3 months prior to last follow-up in cancer-free patients (P < 0.05). In 92.9% of patients with biliary cancer, we found an increase in CA19-9 of >46.23% in the year prior to cancer diagnosis. Conclusions CA19-9 in patients with primary sclerosing cholangitis is highly individual, and the reference change value should be preferred to reference intervals. In this study, CA19-9 remained stable in patients who were cancer-free but increased early in those who developed biliary tract cancer. Regular CA19-9 measurement might improve early detection of these malignancies. 
700 1 |a Brune, Maik  |d 1974-  |e VerfasserIn  |0 (DE-588)130611883  |0 (DE-627)504641948  |0 (DE-576)298297930  |4 aut 
700 1 |a Knierim, Johannes  |d 1925-2015  |e VerfasserIn  |0 (DE-588)1110039905  |0 (DE-627)865210411  |0 (DE-576)475689615  |4 aut 
700 1 |a Weiss, Karl Heinz  |d 1976-  |e VerfasserIn  |0 (DE-588)130069531  |0 (DE-627)489615465  |0 (DE-576)297980203  |4 aut 
700 1 |a Rupp, Christian  |d 1982-  |e VerfasserIn  |0 (DE-588)1023613190  |0 (DE-627)718110765  |0 (DE-576)367149435  |4 aut 
700 1 |a Gotthardt, Daniel  |d 1973-  |e VerfasserIn  |0 (DE-588)12903293X  |0 (DE-627)387885137  |0 (DE-576)297458027  |4 aut 
773 0 8 |i Enthalten in  |t Alimentary pharmacology & therapeutics  |d Oxford : Blackwell Science, 1987  |g 49(2019), 6, Seite 769-778  |h Online-Ressource  |w (DE-627)320425290  |w (DE-600)2003094-0  |w (DE-576)091140137  |x 1365-2036  |7 nnas  |a Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis 
773 1 8 |g volume:49  |g year:2019  |g number:6  |g pages:769-778  |g extent:10  |a Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis 
856 4 0 |u https://doi.org/10.1111/apt.15146  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15146  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190401 
993 |a Article 
994 |a 2019 
998 |g 12903293X  |a Gotthardt, Daniel  |m 12903293X:Gotthardt, Daniel  |d 50000  |e 50000PG12903293X  |k 0/50000/  |p 6  |y j 
998 |g 1023613190  |a Rupp, Christian  |m 1023613190:Rupp, Christian  |d 910000  |d 910100  |e 910000PR1023613190  |e 910100PR1023613190  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 130069531  |a Weiss, Karl Heinz  |m 130069531:Weiss, Karl Heinz  |d 910000  |d 910100  |e 910000PW130069531  |e 910100PW130069531  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 1110039905  |a Knierim, Johannes  |m 1110039905:Knierim, Johannes  |p 3 
998 |g 130611883  |a Brune, Maik  |m 130611883:Brune, Maik  |d 910000  |d 910100  |e 910000PB130611883  |e 910100PB130611883  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1045619833  |a Wannhoff, Andreas  |m 1045619833:Wannhoff, Andreas  |d 50000  |e 50000PW1045619833  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1662607059  |e 3417589851 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"769-778","year":"2019","extent":"10","issue":"6","volume":"49","text":"49(2019), 6, Seite 769-778"},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Blackwell Science","dateIssuedKey":"1987","publisherPlace":"Oxford","dateIssuedDisp":"1987-"}],"language":["eng"],"title":[{"title":"Alimentary pharmacology & therapeutics","title_sort":"Alimentary pharmacology & therapeutics"}],"id":{"eki":["320425290"],"doi":["10.1111/(ISSN)1365-2036"],"zdb":["2003094-0"],"issn":["1365-2036"]},"disp":"Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitisAlimentary pharmacology & therapeutics","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 25.03.2022","Ungezählte Beil.: Supplement"],"titleAlt":[{"title":"Alimentary pharmacology and therapeutics"}],"pubHistory":["1.1987 -"],"recId":"320425290"}],"physDesc":[{"extent":"10 S."}],"person":[{"roleDisplay":"VerfasserIn","family":"Wannhoff","role":"aut","display":"Wannhoff, Andreas","given":"Andreas"},{"role":"aut","display":"Brune, Maik","given":"Maik","family":"Brune","roleDisplay":"VerfasserIn"},{"given":"Johannes","role":"aut","display":"Knierim, Johannes","family":"Knierim","roleDisplay":"VerfasserIn"},{"family":"Weiss","roleDisplay":"VerfasserIn","role":"aut","display":"Weiss, Karl Heinz","given":"Karl Heinz"},{"display":"Rupp, Christian","role":"aut","given":"Christian","family":"Rupp","roleDisplay":"VerfasserIn"},{"given":"Daniel","display":"Gotthardt, Daniel","role":"aut","family":"Gotthardt","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Andreas Wannhoff, Maik Brune, Johannes Knierim, Karl Heinz Weiss, Christian Rupp, Daniel N. Gotthardt"]},"origin":[{"dateIssuedDisp":"27 January 2019","dateIssuedKey":"2019"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 01.04.2019"],"recId":"1662607059","id":{"doi":["10.1111/apt.15146"],"eki":["1662607059"]},"title":[{"title_sort":"Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis","title":"Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis"}]} 
SRT |a WANNHOFFANLONGITUDIN2720